Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574097 | 0.84 | CHRM2 (0.41) | SMN1; SMN2CCR2CHRM2CHRM1CHRM3 | |
| SCHEMBL6576039 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2CCR2CHRM2CHRM1CHRM3 | |
| SCHEMBL6575940 | 0.80 | CHRM2 (0.47) | SMN1; SMN2CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL6574143 | 0.76 | CHRM2 (0.46) | SMN1; SMN2CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL6577617 | 0.76 | CYP3A4 (0.46) | CHRM2CHRM1CHRM3SIGMAR1OPRK1 | |
| SCHEMBL6576172 | 0.75 | CHRM2 (0.46) | CHRM2CHRM1CHRM3ALDH1A1SIGMAR1 | |
| SCHEMBL6576125 | 0.69 | KIF11 (0.41) | SMN1; SMN2CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL2636462 | 0.67 | PDK1 (0.44) | CCR2TSHRHTR2AHTR2C | |
| SCHEMBL11638488 | 0.67 | SMN1; SMN2 (0.96) | SMN1; SMN2CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL25471504 | 0.67 | TSHR (0.36) | CCR2SIGMAR1OPRK1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383730-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | Aryx Therapeutics (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002096855-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2002-12-05 | — | — | WO | claimed |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | ARYX THERAPEUTICS | 2002-11-14 | — | — | US | claimed |
| EP-1383730-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | Aryx Therapeutics (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002096855-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | ARYX THERAPEUTICS | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | CHRM3, CHRM5, CHRM2 | SMN1; SMN2 782/4885CCR2 1443/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.